Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
11 Mar 24
EFFECT
Notice of effectiveness
6 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Mar 24
POS AM
Prospectus update (post-effective amendment)
4 Mar 24
25
Voluntary exchange delisting
1 Mar 24
6-K
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
21 Feb 24
6-K
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
19 Jan 24
6-K
PHAXIAM Provides Business and Financial Update
16 Nov 23
6-K
Current report (foreign)
25 Oct 23
6-K
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
11 Oct 23
6-K
PHAXIAM Therapeutics and Vetophage Announce
5 Oct 23
6-K
I.Certification of the Person Responsible for the Half-year Financial Report
26 Sep 23
6-K
Current report (foreign)
21 Sep 23
6-K
PHAXIAM Therapeutics announces the completion of its reverse share split
18 Sep 23
6-K
Current report (foreign)
15 Sep 23
6-K
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
7 Sep 23
6-K
PHAXIAM Therapeutics announces a reverse share split of
27 Jul 23
6-K
Current report (foreign)
30 Jun 23
424B3
Prospectus supplement
29 Jun 23
6-K
Current report (foreign)
28 Jun 23
6-K
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
21 Jun 23
6-K
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
15 Jun 23
6-K
Current report (foreign)
12 Jun 23
6-K
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
6 Jun 23
6-K
Current report (foreign)
26 May 23
F-X
Appointment of agent for service of process by issuers registering securities
24 May 23
6-K
Exemption Document Prepared In Connection with the Merger by Absorption of Pherecydes Pharma by Erytech Pharma
24 May 23
6-K
ERYTECH Provides Update on the Announced Combination with PHERECYDES
16 May 23
6-K
ERYTECH Provides Business and Financial Update for the First Quarter of 2023
10 May 23
6-K
ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market
18 Apr 23
20-F
2022 FY
Annual report (foreign)
28 Mar 23
6-K
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
23 Mar 23
6-K
This press release does not constitute an offer to purchase any securities
16 Feb 23
6-K
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
22 Nov 22
6-K
ERYTECH Announces Receipt of Nasdaq Notice
14 Oct 22
6-K/A
I.Certification of the Person Responsible for the Half-year Financial Report
12 Sep 22
Latest ownership filings
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
23 Dec 22
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 22
SC 13G
BIOTECHNOLOGY VALUE FUND L P
10 Mar 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
29 Jan 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
12 Jan 21
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
13 Oct 20
SC 13D/A
Erytech Pharma S.A.
8 Nov 18
SC 13D/A
Erytech Pharma S.A.
8 Nov 18
SC 13D
Erytech Pharma S.A.
18 Jul 18
SC 13D/A
Erytech Pharma S.A.
2 Jul 18
SC 13G/A
Erytech Pharma S.A.
2 Jul 18
SC 13G
Erytech Pharma S.A.
2 Jan 18
SC 13D
Erytech Pharma S.A.
16 Nov 17